As of November 10, 2026, NextCure, Inc. is a publicly traded company (Nasdaq: NXTC). The largest holder reporting an active stake on Schedule 13D is Sofinnova Venture Partners IX, L.P., at 7.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include ADAR1 Capital (15.8%), Ikarian Capital, LLC (9.99%), JP Sailing Capital Ltd (9.9%) (Schedule 13D/A, March 5, 2026).
Is this your company?
About to sign with, pay or invest in NextCure, Inc.? See the free Snapshot first.
Free to see. No signup.
Is NextCure, Inc. a real, registered company?
- NextCure, Inc. files with the SEC under CIK 1661059 (its SEC filings).
- Its shares are listed under the ticker NXTC on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Baltimore, Maryland, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under NextCure, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-07-14).
- Leadership changes: the latest reported is Udayan Guha, Chief Medical Officer (Form 8-K filed 2026-10-30). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names JP Sailing Capital Ltd (filed 2026-10-20).
Who are NextCure, Inc.'s owners and officers?
NextCure, Inc.: incorporated in Delaware; business address in Baltimore, Maryland; industry Pharmaceutical Preparations (Form D, 2026-10-30).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Director (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
- : Executive Officer (Form D, 2025-12-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-20 | Jp Sailing Capital LTD | 9.9% |
| Schedule 13G/A, 2026-08-14 | Ikarian Capital, LLC | 9.99% |
| Schedule 13G, 2026-08-14 | Adar1 Capital Management, LLC | 15.8% |
| Schedule 13G/A, 2026-08-14 | Squadron Master Fund LP | 1.6% |
| Schedule 13G/A, 2026-08-13 | Affinity Asset Advisors, LLC | 6.4% |
| Schedule 13G, 2026-08-12 | Adage Capital Management, L.P. | 7.67% |
| Schedule 13G/A, 2026-05-13 | Silverarc Capital Management, LLC | 4.9% |
| Schedule 13G/A, 2026-05-06 | Simcere Zaiming, Inc. | 9.4% |
| Schedule 13D/A, 2026-03-05 | Sofinnova Venture Partners Ix, L.P. ("Svp Ix") | 7.1% |
| Schedule 13G, 2026-02-17 | Ikarian Capital, LLC | 9.99% |
| Schedule 13G/A, 2026-02-17 | Squadron Master Fund LP | 9.9% |
| Schedule 13G/A, 2026-02-13 | Pfizer Inc. (Irs Identification No.: 13-5315170) | 3% |
Questions about who owns NextCure, Inc.
Who owns NextCure, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of NextCure, Inc.: Adar1 Capital Management, LLC (15.8%, Schedule 13G, filed 2026-08-14), Ikarian Capital, LLC (9.99%, Schedule 13G/A, filed 2026-08-14), Jp Sailing Capital LTD (9.9%, Schedule 13G, filed 2026-10-20), Simcere Zaiming, Inc. (9.4%, Schedule 13G/A, filed 2026-05-06) and Adage Capital Management, L.P. (7.67%, Schedule 13G, filed 2026-08-12); 2 more are listed above.
Who are the largest shareholders of NextCure, Inc.?
By the share each holder's latest filing reports, the largest holders of NextCure, Inc. on this page are Adar1 Capital Management, LLC (15.8%), Ikarian Capital, LLC (9.99%) and Jp Sailing Capital LTD (9.9%).
When did Adar1 Capital Management, LLC buy into NextCure, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Adar1 Capital Management, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 15.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on NextCure, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NextCure, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NextCure, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-30 | Udayan Guha | Chief Medical Officer | departed | 2026-10-31 |
Which insiders own NextCure, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- ADAR1 Capital, a 10% owner: 737,956 shares (16.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-09).
- , a 10% owner: 737,956 shares (16.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-09).
- Simcere Zaiming Pharmaceutical Co., Ltd.: 308,636 shares (6.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-12).
- Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.: 308,636 shares (6.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-12).
- Jinsheng Ren: 308,636 shares (6.7% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-08-12).
Shares outstanding: 4,577,359 as of 2026-07-31, from the company's latest SEC cover page.
How much has NextCure, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-12-10 | $21.50M | $21.50M |
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-07-14).
Keep reading
More on NextCure, Inc. and the records around it.
NextCure, Inc. elsewhere on the record
- Leadership changes Oct 2026
- 5%+ stake filings Oct 2026
- Layoff notices Jul 2026
- Form D filing Dec 2025
Companies that share a holder
- Sofinnova Venture Partners IX, L.P. ("SVP IX") also filed stake reports on 1 other company: ArriVent Biopharma, Inc. (Mar 2026)
- Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), Allogene Therapeutics, Inc. (Feb 2026)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/nextcure